This Plain Language Summary of Publication article (PLSP) from Future Oncology outlines the management of cytokine release syndrome (CRS) and infections – two side effects observed in the MajesTEC-1 clinical trial that evaluated teclistamab treatment in multiple myeloma patients.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma’ and was published in Cancer.

‘Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study’ and was published in Cancer.

Visit ACS Journals using the link to read the original article.

Visit ACS Journals using the link to read the original article.